Table 2.
Transplant patient’s demographic and clinical characteristics at study enrollment
| Patientsa (n = 53) |
|
|---|---|
| n (%) | |
| Age, years, mean (±SD) | 45.4 (±14.4)b |
| Gender, female | 18 (34.0) |
| Race | |
| White | 37 (69.8) |
| African American | 7 (13.2) |
| Other | 9 (17.0) |
| Ethnicity | |
| Hispanic or Latino | 5 (9.4) |
| Education | |
| Bachelor’s or graduate degree | 28 (53.9)b |
| Baseline ECOG | |
| 0 | 22 (41.5) |
| 1 | 30 (56.6) |
| 2 | 1 (1.9) |
| Primary disease | |
| Lymphoma/MM | 27 (50.9) |
| Nonmalignant disease | 6 (11.3) |
| CLL/CML | 8 (15.1) |
| ALL/AML | 5 (9.4) |
| MDS | 4 (7.5) |
| Solid tumor | 2 (3.8) |
| CML and Hodgkin’s (dual diagnosis) | 1 (1.9) |
| Conditioning intensity | |
| Reduced intensity conditioning | 45 (86.5)b |
| Myeloablative | 7 (13.5)b |
| Stem cell source | |
| Peripheral blood | 51 (98.1)b |
| Cord | 1 (1.9)b |
| HLA disparity/donor | |
| HLA—well or partially matched related | 29 (55.8)b |
| HLA—well or partially matched unrelated | 20 (38.5)b |
| HLA—mismatched related | 3 (5.8)b |
| Disease status | |
| CR | 10 (18.9) |
| PR | 8 (15.1) |
| Stable | 14 (26.4) |
| PD | 12 (22.6) |
| Severe diseasec | 9 (17.0) |
MM: multiple myeloma; CLL: chronic lymphocytic leukemia; AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; CML: chronic myelogenous leukemia; ALL: acute lymphoblastic leukemia; ECOG: Eastern Cooperative Oncology Group; HLA: human leukocyte antigen; SD: standard deviation; CR: complete remission; PR: partial remission PD: progressive disease.
a
Patients (n = 53) correspond to caregivers (n = 73). 52 patients correspond to active caregivers (n = 66).
b
n = 52.
c
Nonmalignant diseases.